Editas Medicine
Biotechnology ResearchView the employees at
Editas Medicine-
Stacy Dobbs VP, Financial Planning Analysis at Editas Medicine
-
Greater Boston
-
Top 5%
Lenae Fiora Process Development Associate at Editas Medicine-
Rising Star
Lisa A. Michaels Executive Leadership | Broad Therapeutic Area Expertise | Focus on Rare and Orphan disease-
Princeton, New Jersey, United States
-
Top 5%
Peter Liu Associate Director of Process Development at Editas Medicine-
Greater Boston
-
Rising Star
Overview
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
-